Image of woman leaving bedroom through number 1-shaped door

LUMRYZ is the first and only single-dose sodium oxybate to help provide daytime symptom control of excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy.1

Orphan Drug Exclusivity

Granted for Major Contribution to Patient Care2

FDA has determined LUMRYZ to be clinically superior* to twice-nightly oxybates2

Once-at-bedtime LUMRYZ dosing was found to be a major contribution to patient care over both XYREM® (sodium oxybate) and XYWAV® (calcium, magnesium, potassium and sodium oxybates).1,2

See FDA findings on clinical superiority*
Image of woman outdoors arranging flowers

LUMRYZ is once at bedtime, for their daytime1

The first and only single-dose sodium oxybate to help provide daytime symptom control of excessive daytime sleepiness and cataplexy.1,3

Delivers treatment throughout the course of a nocturnal sleep period4 See how it works
Established safety and demonstrated efficacy across 3 co-primary endpoints (MWT, CGI-I, weekly cataplexy attacks) and select secondary endpoint (ESS)1,3 Explore efficacy
RYZUP Support Services dedicated to helping your patients and your office About RYZUP

Help improve their daytime symptoms with a single-dose sodium oxybate.1,4

Start or switch your patients on the appropriate dose of LUMRYZ.1

Start or switch

Are you REMS-certified?

As with other sodium oxybate treatments, certification in the LUMRYZ Risk Evaluation and Mitigation Strategy (REMS) is required to prescribe LUMRYZ.

Ready to get patients on treatment?

Enrolling patients in the LUMRYZ REMS and RYZUP™ Support Services is required to ensure your patients receive LUMRYZ as prescribed. What to expect when getting started

*Based on a determination of Orphan Drug Exclusivity by the FDA Office of Orphan Products Development between LUMRYZ and XYREM or XYWAV. There are no head-to-head data for LUMRYZ and XYREM or XYWAV.


  1. References: 1. LUMRYZ. Package insert. Chesterfield, MO: Avadel Pharmaceuticals; 2023. 2. US Food and Drug Administration. Clinical superiority findings. Accessed May 1, 2023. 3. Kushida CA, Shapiro CM, Roth T, et al. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy. Sleep. 2022;45(6):1-11. 4. Bogan R, Thorpy MJ, Winkelman JW, et al. Randomized, crossover, open-label study of the relative bioavailability and safety of FT218, a once-nightly sodium oxybate formulation: phase 1 study in healthy volunteers. Sleep Med. 2022;100:442-447.